References
- Endicott J. A., Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu. Rev. Biochem. 1989; 58: 137–71
- Nooter K., Herweijer H. Multidrug resistance (mdr) in human cancer. Br. J. Cancer 1991; 63: 663–69
- Goldstein L. J., Galski H., Fojo A., et al. Expression of a multidrug resistance gene in human cancers. J. Nat. Cancer Inst. 1989; 81: 116–24
- Pirker R., Wallner J., Geissler K., et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 1991; 83: 708–12
- Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemia: Correlation with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–92
- Sato H., Preisler H., Day R., et al. MDR1 transcript level as a indication of resistant disease in acute myelogenous leukemia. British J. Hematol. 1990; 75: 340–45
- Holmes J., Jacobs A., Carter G., et al. Multidrug resistance in hematopopietic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia. Br. J. Hematol. 1989; 72: 40–4
- Mattern J., Efferth T., Bak M., et al. Detection of P-glycoprotein in human leukemias using monoclonal antibodies. Blut 1989; 58: 215–17
- Solary E., Bidan J. M., Calvo F., et al. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukemia and myeloma. Leukemia 1991; 5: 592–97
- Campos L., Guyotat D., Archimbaud E., et al. Clinical significance of multidrug resistance P-glycoprotein expression an acute nonlymphocytic leukemia cells at diagnosis. Blood 1992; 79: 413–76
- Musto P., Melillo L., Lombardi G., Matera R., Di Giorgio G., Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br. J. Hematology 1991; 77: 50–3
- Zhou D., Marie J. P., Suberville A. M., et al. Comparison of mRNA mdr1 and P-glycoprotein expression in acute myelogenous leukemia. Leukemia. 1992, in press.
- Kohno K., Sato S., Takano H., Matsuo K., Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophysic. Res. Comm. 1989; 165: 1415–21
- Slater L., Sweet P., Stupecky M., et al. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 1986; 77: 1405–08
- Marie J. P., Bastie J. N., Coloma F., et al. A phase I-II trial of cyclosporine with etoposide and mitoxantrone in acute leukemia. Proceed. Amer. Soc. Clon. Onco. 1992; 11: 275
- Kartner N., Evernden-Porelle D., Bradley G., et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820–23
- Ma D. D. F., Davey R. A., Harman D. H., et al. Detection of multidrug resistant phenotype in acute nonlymphoblastic leukemia. Lancet 1987; 1: 135–37
- Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459–62
- Sugimoto K., Toyoshima H., Sakai R., et al. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153–56
- Ahuja H. G., Foti A., Bar-Eli M., Cline M. J. The pattern of mutational involvement of RAS genes in human hematological malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75: 1684–90
- Hayes J. D., Wolf C. R. Glutathione transferases in drug resistance in glutathione conjugaison: mechanisms and biological significance, H. Sies, B. Kettener. Academic Press, New York, 315–55. 1988
- Beck W. T. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J. Natl. Cancer Institl. 1989; 81: 1683–85